Bryden Considine, DO

Novel Targets and Precision Medicine for Prostate Cancer—Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer

April 15, 2019

Bryden Considine, DO
Daniel P. Petrylak, MD

In this article, we review the current use of and future direction for genetic testing and tumor profiling in patients with metastatic castration-resistant prostate cancer.

READ >>

Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care—Part 1: The Non-Androgen–Targetable Pathways in Castration-Resistant Prostate Cancer

March 13, 2019

Bryden Considine, DO
Daniel P. Petrylak, MD

Here, we review the current use and future direction of novel therapeutic targets in the treatment of castration-resistant prostate cancer.

READ >>